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CLINICAL HYPERTHERMIA PILOT STUDIES, THOMAS JEFFERSON UNIVERSITY HOSPITAL
RESULTS OF 42.50C. ADJUVANT TO IRRADIATION
John Fazekas, M.D. and Ted Nerlinger, B.S.
Department of Radiation Therapy and Nuclear Medicine
Thomas Jefferson University Hospital, Philadelphia, Pennsylvania 19107
The phase I (February 1979 - May 1980) hyperthermia experience consists of twentysix cases, twenty of whom received x-ray therapy (electron beam) plus an averaqe of
eight hyperthermia sessions (twice weekly at 42.5 - 43.5°C intralesional temperature
for 40 minutes). Seventeen of the patients were heated with a 2450 microwave MHZ
generator in conjunction with surface heating (circulating water bag at 45°C). AGA
thermograms were valuable in assessing superficial blood flow documenting heating
patterns, and in predicting potential overheating which may manifest by superficial
burns (blisters). Although the study is non-randomized and patient numbers small, a
complete response of 50% (5 of 10) was noted amongst those patients re-treated to the
chest wall for breast carcinoma recurrence following prior mastectomy and radiation
therapy. The combined response (CR + PR) amongst this largest category was an
encouraging 8 of 10 with follow-up averaging 5 months. The response amongst the 22
evaluable cases was mixed and variable, with 6 showing CR, 6 a PR and combined response
of 55% (12/22), The results attained to date in this pilot project have been sufficiently encouraging to warrant expansion of the techniques of patient categories. The
27.12 MHZ (500 watt output) water-immersed (RCA) ridge waveguide offers considerable
promise in expansion of potential eligible cases to include deep seated tumors within
the pelvis, lung apex, or deep muscular (extremity) regions.
Introduction
The ability of hyperthermia to function as an adjuvant to irradiation has been
unequivocably demonstrated at the laboratory level. •''^ Under experimental conditions,
a significant enhancement in radiation c e l l - k i l l has been noted^'** depending upon the
cell system, radiation dose fraction, and timing of x-ray and heat dosage (timeduration and centigrade degrees sustained). Mechanisms of radiation-heat interpretations
are not fully understood but these four mechanisms may be involved:
1. interference with repair of sublethal radiation damage (Dq on cell survival
curve);
2.

production of lethal cell membrane damage (perhaps independent of irradiation);

3. direct cellular lethality (especially those cells at low pH and those in the
S-phase of the mitotic cycle), resulting in a change in the DQ on cell-survival graph;
and
4.

"other" effects, poorly understood and not well documented.

This report will deal with the clinical hyperthermia t r i a l at Thomas Jefferson
University Hospital, attempting to utilize this modality adjuvant to irradiation for
palliation of advanced, inoperable (superficial) tumor masses. In a fashion similar
to that reported by D. Luk^ and J.H. Kim,^ radiofrequency and/or microwave heating

3^

sources were utilized. Only superficial localized or limited regional masses were
considered candidates regardless of the histologic subtype or organ of origin.
Ultrasonic heating techniques, as reported by Marmor et al^ have not been developed
at Jefferson but are in the planning phase.
Materials and Patients Selected
Between February, 1979 and May, 1980, twenty-six (26) patients have submitted to
the clinical hyperthermia program. Criteria for selection and acceptance included the
following:
1. histologically proven malignancy (each metastatic nodule/mass need not be
biopsied);
2. clinical failure with all other reasonable therapeutic measures (surgery,
prior radiotherapy, chemotherapy/hormones);
3. ability to heat the tumor mass with existing (RF-microwave) equipment to 42.5°C
(intralesional) for 35-40 minutes for six heat sessions;
4.

signing informed consent; and

5. prior radiotherapy (even to "tolerance" doses of 5000-6000 rad) is not
considered a contraindication.
Since we hoped to capitalize upon the altered (hypoxic-acidic) status of tumor
cells following irradiation (especially after sublethal radiation events), x-ray therapy
was given f i r s t , followed by heat administration generally utilizing this protocol
sequence:
Electron beam therapy,
200-250 rad to volume,
4 fractions/week

"Immediate" hyperthermia
42.5 - 43.5^0 (intralesional) ^
x 40 minutes twice weekly

Repeat cycle q. week
for total of 3000-5000
rad and 6-8 heat
treatments

Pre-treatment evaluation includes assessment of tumor volume using modern techniques
of ultrasound, CT scanning, and appropriate radiographic studies. An AGA thermographic
camera assessed the superficial vascularity in each treated area prior to and following
heat sessions, hoping to predict areas which might heat readily or overheat (large
ischemic tumor masses tend to act as heat "sinks"). Temperature measurements during
heat therapy were obtained every five minutes with the RF or microwave source off for
15-30 seconds utilizing Bailey thermocouple equipment. Since metal objects cannot be
l e f t within RF or microwave fields, an 18G plastic intracath is inserted under local
anesthesia directly within the tumor mass, placed at different depths on each heating
session (0.5 cm, 1.0 cm, 1.5 cm). Surface temperature readings are also monitored
underneath a thin plastic bag of circulating hot water kept at 45°C under thermostatic
control. The available fibre-optic equipment (Ramal) was found to be unreliable and
was, in effect, discarded.
Circulating cold (ice) water was added to the skin surface when inadvertent overheating caused a second degree burn (blister) or when post-treatment AGA thermograms
showed an area of skin heating exceeding 45°C,
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Results
Table 1 summarizes the treatment parameters among twenty-six patients entered and
treated with hyperthermia by May 20, 1980. Five patients could not receive additional
heat therapy and received heat alone (cases 1, 7, 8, 11, and 13). The additional 21
cases received combined therapy (XRT plus immediate heat). Chest wall recurrences
(failure of surgery, radiotherapy and chemotherapy) accounted for one-half of these
21 cases. Five of these ten (50%) achieved complete response (disappearance of all
tumor by vision and palpation) while an additional three patients experienced a partial
response (> 50% tumor shrinkage), while only two failures (< 50% response of tumor)
were noted. The average radiation dosage was 2750 rad in combination with 7 heat
sessions (average), two per week for one month.
The second largest group submitting to hyperthermia consisted of patients with
superficial metastatic (skin) nodules or lymph nodes secondary to squamous carcinoma
arising in the head and neck (3 cases) or lung (6 cases) regions. Forty-four percent
of these (four) have shown a CR, while no response (< 50% shrinkage) was observed among
another identical group (four). Miscellaneous patients receiving treatment included
primaries in the colon, ovary, skin (melanoma) and lymph nodes (histologic lymphoma),
or soft tissues (liposarcoma). The clinical results amongst the 22 evaluable patients
are summarized in Table 2.
The f i r s t five patients were heated with RF techniques (18-25 MHZ), with applicators placed directly over the skin surface insulated from the skin by plastic materials.
Unfortunately, these 'bapacitor-RF" techniques led to skin blisters in every case in
spite of attempts to prevent skin burning. The remaining 20 cases were heated using
external heat applicators, raised 2-5 cm from the skin surface. A 2450 microwave
generator (100 watt max, output) was used in 17 of these 20 patients, 27,12 MHZ in the
remaining 3 cases. No significant skin complication, no late effects, and no enhancement of the radiation reaction was observed among the later patients.
We will soon be expanding the program to include candidates with inoperable,
recurrent and previously treated tumor located wthin the lower pelvis (prostate,
bladder, rectum, cervix) in a phase I - I I t r i a l of the 27.12 MHZ ridge waveguide (RCA)
applicator.
Representative case reports will be presented during the hyperthermia symposium,
treatment techniques further degined, and pictoral representative of AGA thermograms
demonstrated. A hand-held 2450 waveguide applicator is capable of producing intralesional temperatures of 43.0°C ± 0,5°C while keeping the surface at 40,0 - 41,0°C,
by rotating the unit to avoid uneven heating.
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Table 1

Case #
Age/Sex

Date
Rx

Primary
Site

Area
Treated

Method
(A)

No. of
(A) Tx

Rad.
Therapy

Results

J Si

1. DV 49 F

2/79

oropharynx 6x9x35 cm

RF alone

4

None

resp <50%
expired of Ca

2. KS 69 F

2/79

adenoca,
breast

35 X 35 cm
chest wall

RF + XRT

9

875/4

blister, NR

3. HR 35 M

4/79

tongue,
squamous

large cerv.
nodes

RF + XRT

5

400/4

resp <50%,
blister,
died 3 mo

LS 59 F

5/79

adenoca,
breast

mult, nodules XRT + RF
chest wall
(retreat)

10

1100/4

2

400/2

regression
of nodules
>50%, died
1 yr

10

500/5

NR

5. LB 65 F

5/79

adenoca,
breast

4 cm mass
chest wall

XRT + RF

6. MD 64

7/79

sarcoma

>10 X 15 cm
buttocks

XRT +
27 MHZ

9

2750/11

softer, but
NR

7. DM 66 F 10/79

adenoca,
breast

1,5 X 1 cm
chest wall

450c H2O +
2450 MiiZ

8

^one

CR, alive &
well at 7 mo

8. MS 72 F

9/79

adenoca,
colon

10 X 10 cm

27 MHZ

7

9. HM 58 F

12/79

adenoca,
breast

1.0 X 1.4 cm XRT +
chest wall
45°C H2O +
2450 MHZ

10, AM 58 M

1/80

orpharynx,
squamous

>10 cm skin
(cerv) mass

3750/17 resp >50%

(Retreat)

4

1600/4

XRT + A

2

4400/22 died of dissem
Ca

7

4400/22 CR, NED 5 mo

melanoma,
skin

4 cm
lymph nodes

12, WS 53 F

12/79

adenoca,
breast

chest wall
XRT + 45°C
(mult, nod,) H2O + 2450

lung

5 X 8 cm
supraclav.
mass

45°C H?0 +
2450 MHZ

42

5000/20 resp >50%,
alive & well
at 5 mo

8

7/79

1/80

bleeding and
size unchanged

XRT +
2450 MHZ

11, CH 50 M

13, JH 73 M

10

None

10

None

alive at 5 mo

NR, died 4/80

Table 1 (continued)
Case #
Age/Sex

Date •
Rx

Primary
Site

Area
Treated

Method
(A)

No, of Rad,
(A) Tx Therapy

Results

14, JB 55 F 1/80

adenoca,
breast

2.6 X 1,5 cm XRT + 45°C
chest wall
H2O + 2450
nodules
MHZ

8

5400/27 CR, alive &
well, 4 mo

15, JJ 66 M 1/80

lung,
squamous

supraclav,
recurrent,
squamous

XRT + 45°C
H2O + ice
H2O + 2450

8

3600/18 >50%, alive
& wel 1, 4 mo

16, RM 63 F 1/80

adenoca,
breast

chest wall

XRT + 45OC
H2O + 2450

6

4035/17 CR, alive &
well, 5 mo

17, JS 42 F 2/80

lung,
squamous

6 cm post,
cerv, mass

XRT + 45°C
H2O + 2450

8

4250/17 >50% resp,
pain gone

18, JS 62 F 3/80

adenoca,
breast

mult.
chest wall

XRT + 450c
H2O + 2450

8

adenoca,
breast

4 cm sternal XRT + 450c
mass
H2O + 2450

7

20, RD 48 M 4/80

1 ung,
squamous

6 X 5 cm mass XRT + 450c
l e f t neck
H2O + 2450

5

ovary

10 cm cutaneous mass

XRT + 450c
H2O + 2450

1

21, AB 55 F 4/80
22, CZ 70 M 5/80

adenoca,
lung

10 cm post,
chest wall
mass

XRT + 45OC
H2O + 2450

6

2800/14 resp <50%

23, JE 71 M 5/80

adenoca,
lung

8 X 6 cm
supraclav.

XRT + 45°C
H2O + 2450

6

2750/11 resp <50%

24, MH 76 F 5/80

histiocytic
lymphoma

2.5 X 2.5 cm XRT + 45°C
nasal cavity H2O + 2450
mass

3

1200/6*

—

25, JS 54 F 5/80

skin,
melanoma

4 X 3 cm
subcutan,
masses

XRT + 450c
H2O + 2450

3

1200/3*

—

26, AM 50 F 5/80

adenoca,
breast

15 X 12 cm
chest wall
ulcer

XRT + 45°C
H2O = 2450

200/1*

—

19, EF 65 F 4/80

* Patients currently under therapy

4?

3000/10 CR at 1 mo
3000/12 CR, alive &
well at 3 mo
2599/10 NR, pt, expired during
Rx
300/1

i '

NP, pt.
admitted

1

Table 7.
Summary of Hyperthermia Experience
(February 1979 - May 1980)
Number of patients treated

26

Response categories
22 evaluable

NR - (<50% shrinkage)
10/22
PR - (>50 tumor shrinkage)
6/22
CR - (disappearance of tumor) 12/22

Histologic Types (Primary)
Breast adenocarcinoma
Lung - squamous or adenoca
Head and neck primaries
Miscellaneous sites
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11
6
3
6
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